The real residual risk in patients with CVD & diabetes: The promise of epigenetics
Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CVD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.
Video navigation menu
Increased lifetime risk for CHD in diabetic patients 00:20
Can intensive glucose control address residual vascular risk in diabetic patients? 01:40
Effect of LDL-c lowering on CV risk reduction in patients with T2DM 02:15
Role of inflammation in T2DM 05:32
Effect of anti-inflammatory interventions in CV patients with diabetes 08:17
Educational information
This lecture was part of a CME accredited symposium: "LDL-c: Done Deal, Next Epigenetics?" during ESC 2018 in Munich, Germany.
Faculty
Prof. Erik Stroes, MD - Professor of Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands
Disclosures
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding
Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: